Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
- MHLW Eyes Information Provisioning on Generic Supplies by Individual Brands
December 24, 2021
- Japan to Revise PMD Law to Create Emergency Approval System, Final Paper Due Out by Year-End
December 23, 2021
- Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
- Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
- Japan to Cut Drug Prices by 1.35% on Medical Cost Basis; No Special Rule for Adjustment Rate This Time
December 22, 2021
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
- Gist of FY2022 Drug Pricing Reform
December 22, 2021
- Look into Relationship Between COVID-19 Vaccination and Adverse Events: MHLW Panel
December 22, 2021
- Mochida’s Inhaled Treprostinil Gets Orphan Status
December 22, 2021
- Japan Expected to Cut Drug, Medical Device Prices by 160 Billion Yen on National Offers Basis
December 21, 2021
- MHLW Panel OKs “Specific-Use” Drug Designation for Dexmedetomidine
December 21, 2021
- Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
- Noxafil Contraindicated for Combined Use with Lonasen, Belsomra
December 20, 2021
- PM Kishida Vows to Move Up Booster, Offer COVID-19 Pill as Japan Girds for Omicron
December 20, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- LDP Study Group Proposal Calls for 2%-Plus Adjustment Rate for 2022 Drug Price Revision
December 16, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…